Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis

• Main Authors: Giorgia Caspani (Author), Simon G.D. Ruffell (Author), WaiFung Tsang (Author), Nigel Netzband (Author), Cyrus Rohani-Shukla (Author), Jonathan R. Swann (Author), Wilfred A. Jefferies (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1096-1186; 10.1016/j.phrs.2024.107338
• Keywords: Psychedelics; Gut microbiota; Gut-brain axis; Personalised medicine; Precision medicine; Psilocybin; Therapeutics. Pharmacology; RM1-950
• Source: Pharmacological Research, Vol 207, Iss , Pp 107338- (2024)

Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around their partial agonism at the serotonin 2 A receptor, leading to enhanced neuroplasticity and brain connectivity changes that underlie positive mindset shifts. However, these accounts fail to recognise that the gut microbiota, acting via the gut-brain axis, may also have a role in mediating the positive effects of psychedelics on behaviour. In this review, we present existing evidence that the composition of the gut microbiota may be responsive to psychedelic drugs, and in turn, that the effect of psychedelics could be modulated by microbial metabolism. We discuss various alternative mechanistic models and emphasize the importance of incorporating hypotheses that address the contributions of the microbiome in future research. Awareness of the microbial contribution to psychedelic action has the potential to significantly shape clinical practice, for example, by allowing personalised psychedelic therapies based on the heterogeneity of the gut microbiota.